BURLINGTON, Mass., Nov. 15, 2010 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that although four out of five surveyed psoriasis patients in the United States who have requested a brand indicate that physicians are willing to comply with their request to be prescribed a specific drug, only 20 percent of surveyed patients indicate that they have asked for a psoriasis drug by name. Given the fact that moderate-to-severe psoriasis patients are underserved by currently available treatment options, this finding suggests that marketers of psoriasis therapies could improve the uptake of their therapies by increasing patient awareness of their drugs through physicians, web sites and patient advocacy groups.

Additionally, surveyed patients with both mild and moderate-to-severe psoriasis at the time of diagnosis were more likely to be diagnosed during their first doctor's visit if they were examined by a dermatologist versus being seen by a primary care physician (PCP). Eighty-five percent of surveyed patients with mild psoriasis and 78 percent of patients with moderate-to-severe psoriasis who were first seen by a dermatologist about their symptoms were diagnosed with psoriasis during their initial examination. However, only between 55 and 60 percent of patients with mild or moderate-to-severe psoriasis were diagnosed with psoriasis during their first examination by a PCP.

The findings are from Decision Resources' new Patient Forum report entitled Underserved Moderate-to-Severe Psoriasis Patients Offer Opportunity for Recently Launched and Emerging Agents. With Patient Forum, users can obtain indispensible primary market research on U.S. patient attitudes and perceptions of both their disease and treatment, with a specific focus on how patient segments within the psoriasis population differ from each other in their behavior and disease characteristics.

"Patient acceptance is critically important to the success of a drug brand and by understanding the perspectives, behaviors and attitudes of patients, drug developers can obtain the information they need to effectively market their existing and emerging products," said Decision Resources Program Manager Jennifer Moniz-Carpenter, M.B.A. "Patient Forum provides primary market research on the patient journey to diagnosis and treatment, how patients perceive their disease and treatment, what drives patient opinion about current treatments and what will prompt patients to request an emerging therapy."

About Decision Resources

Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

Decision Resources, Inc.

Christopher Comfort



SOURCE Decision Resources

Driven by the Uptake of Several Emerging Agents, the MRSA Drug Market Will Increase From $631 Million in 2009 to $752 Million in 2019

View Now